The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C. albicans are S 0.03 mg/L and for C. glabrata, C. tropicalis and C. krusei S 0.06 mg/L. C. parapsilosis was not regarded a good target for anidulafungin. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly
AbstractThe European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Su...
Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungi...
The echinocandins are recommended as first-line therapy for Candida species infections, but drug res...
Item does not contain fulltextThe European Committee on Antimicrobial Susceptibility Testing-Subcomm...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
Item does not contain fulltextThe European Committee on Antimicrobial Susceptibility Testing-Subcomm...
The efficacy of anidulafungin is driven by the area under the concentration-time curve (AUC)/MIC rat...
10.1128/AAC.02020-13Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laborat...
Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not availa...
Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida...
Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have dr...
This study addressed the application of anidulafungin as a surrogate marker to predict the susceptib...
Item does not contain fulltextSusceptibility testing of fungi and development of interpretative brea...
AbstractThe European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Su...
Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungi...
The echinocandins are recommended as first-line therapy for Candida species infections, but drug res...
Item does not contain fulltextThe European Committee on Antimicrobial Susceptibility Testing-Subcomm...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
AbstractThe European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Su...
Item does not contain fulltextThe European Committee on Antimicrobial Susceptibility Testing-Subcomm...
The efficacy of anidulafungin is driven by the area under the concentration-time curve (AUC)/MIC rat...
10.1128/AAC.02020-13Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laborat...
Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not availa...
Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida...
Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have dr...
This study addressed the application of anidulafungin as a surrogate marker to predict the susceptib...
Item does not contain fulltextSusceptibility testing of fungi and development of interpretative brea...
AbstractThe European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Su...
Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungi...
The echinocandins are recommended as first-line therapy for Candida species infections, but drug res...